TG
Therapeutics, Inc.
July 18, 2018
Securities and Exchange
Commission
Department of Corporation
Finance
Washington, D.C.
20549
Attn: Ms. Christine
Westbrook
|
|
Via:
|
EDGAR Submission
|
|
|
Re:
|
TG Therapeutics,
Inc.
|
Registration Statement on Form
S-3
Filed July 9,
2018
File No.
333-226097
Ladies and
Gentlemen:
TG Therapeutics, Inc. (the
“Company”), hereby requests that the effective date for
the Registration Statement referred to above be accelerated so that
it will be declared effective at 9:00 a.m. (ET) on July 23, 2018 or
as soon as practicable thereafter, pursuant to Rule 461 of the
Securities Act of 1933, as amended.
The Company acknowledges that (i)
should the Commission or the staff of the Commission, acting
pursuant to delegated authority, declare the filing effective, such
declaration does not foreclose the Commission from taking any
action with respect to the filing; (ii) the action of the
Commission or the staff of the Commission, acting pursuant to
delegated authority, in declaring the filingeffective, does not
relieve the Company from its full responsibility for the adequacy
and accuracy of the disclosure in the filing; and (iii) the Company
may not assert the declaration of effectiveness as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.
Please contact Mark F. McElreath of
Alston & Bird LLP with any questions or comments at
212-210-9595. Thank you for your assistance with this
filing.
|
|
TG THERAPEUTICS,
INC.
|
||
|
|
|
|
|
|
|
By:
|
/s/ Sean
Power
|
|
|
|
|
Sean Power
|
|
|
|
|
Chief Financial
Officer
|
|
|
|
cc:
|
Mark F.
McElreath
|
|
|